SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-011995 to Denali SPAC Holdco, Inc. (CIK 0001964657)

Denali SPAC Holdco, Inc. (CIK 0001964657)
Date: Nov. 2, 2023 · CIK: 0001964657 · Accession: 0000000000-23-011995

AI Filing Summary & Sentiment

File numbers found in text: 333-270917

Date
November 2, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Denali SPAC Holdco, Inc. (CIK 0001964657)

Letter

United States securities and exchange commission logo November 2, 2023 Jiandong (Peter) Xu President Denali SPAC Holdco, Inc. 437 Madison Avenue, 27th Floor New York, NY 10022 Re:Denali SPAC Holdco, Inc. Amendment No. 4 to Registration Statement on Form S-4 Filed October 20, 2023 File No. 333-270917 Dear Jiandong (Peter) Xu: We have reviewed your amended registration statement and have the following comment(s). Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our September 15, 2023 letter. Amendment No. 4 to Registration Statement on Form S-4, Filed October 20, 2023 Shareholder Proposal No. 1 - The Business Combination Proposal Projected Financial Information, page 139 1.We note your response to prior comment 4 and your disclosure on page 140 where you state that "those utilizing the information could add their own risk adjustment for success of FDA approval. Typically, the earlier the product is in the development cycle, the lower the probability of success compared to products that are further along in the development cycle." Please revise these statements so as to not (i) indirectly disclaim liability for statements in your registration statement and (ii) create any potential implication that because your product candidates are in clinical trials they are more likely to be approved and note the risks involved in assuming all of your product candidates will be approved. Please also revise to address the reliability of the projections related to the later years presented.

FirstName LastNameJiandong (Peter) Xu Comapany NameDenali SPAC Holdco, Inc. November 2, 2023 Page 2 FirstName LastName Jiandong (Peter) Xu Denali SPAC Holdco, Inc. November 2, 2023 Page 2 Shareholder Proposal No. 5 - The Non-Binding Governance Proposals Proposal No. 5F: Delaware as Exclusive Forum, page 171 2.We note your response to prior comment 7. On page I-6 you state that the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. Elsewhere in the registration statement, such as on page 171, you state that the United States District Court for the District of Delaware will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933. Further, on page 173 you state that "the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court located within the State of Delaware or, if no court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware), to the fullest extent permitted by law, will be the sole and exclusive forum for the types of actions or proceedings under Delaware statutory or common law for the resolution of any complaint asserting a cause of action arising under the Securities Act." Please reconcile these disclosures. Please contact Jeanne Bennett at 202-551-3606 or Brian Cascio at 202-551-3676 if you have questions regarding comments on the financial statements and related matters. Please contact Jessica Ansart at 202-551-4511 or Lauren Nguyen at 202-551-3642 with any other questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Andy Tucker

Show Raw Text
United States securities and exchange commission logo
November 2, 2023
Jiandong (Peter) Xu
President
Denali SPAC Holdco, Inc.
437 Madison Avenue, 27th Floor
New York, NY 10022
Re:Denali SPAC Holdco, Inc.
Amendment No. 4 to Registration Statement on Form S-4
Filed October 20, 2023
File No. 333-270917
Dear Jiandong (Peter) Xu:
            We have reviewed your amended registration statement and have the following
comment(s).
            Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
            After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments. Unless we note otherwise,
any references to prior comments are to comments in our September 15, 2023 letter.
Amendment No. 4 to Registration Statement on Form S-4, Filed October 20, 2023
Shareholder Proposal No. 1 - The Business Combination Proposal
Projected Financial Information, page 139
1.We note your response to prior comment 4 and your disclosure on page 140 where you
state that "those utilizing the information could add their own risk adjustment for success
of FDA approval. Typically, the earlier the product is in the development cycle, the lower
the probability of success compared to products that are further along in the development
cycle." Please revise these statements so as to not (i) indirectly disclaim liability for
statements in your registration statement and (ii) create any potential implication that
because your product candidates are in clinical trials they are more likely to be approved
and note the risks involved in assuming all of your product candidates will be approved.
Please also revise to address the reliability of the projections related to the later years
presented.

 FirstName LastNameJiandong (Peter) Xu
 Comapany NameDenali SPAC Holdco, Inc.
 November 2, 2023 Page 2
 FirstName LastName
Jiandong (Peter) Xu
Denali SPAC Holdco, Inc.
November 2, 2023
Page 2
Shareholder Proposal No. 5 - The Non-Binding Governance Proposals
Proposal No. 5F: Delaware as Exclusive Forum, page 171
2.We note your response to prior comment 7. On page I-6 you state that the federal district
courts of the United States shall be the exclusive forum for the resolution of any complaint
asserting a cause of action arising under the Securities Act of 1933, as amended.
Elsewhere in the registration statement, such as on page 171, you state that the United
States District Court for the District of Delaware will be the exclusive forum for the
resolution of any complaint asserting a cause of action arising under the Securities Act of
1933. Further, on page 173 you state that "the Court of Chancery of the State of Delaware
(or, if the Court of Chancery does not have jurisdiction, another state court located within
the State of Delaware or, if no court located within the State of Delaware has jurisdiction,
the federal district court for the District of Delaware), to the fullest extent permitted by
law, will be the sole and exclusive forum for the types of actions or proceedings under
Delaware statutory or common law for the resolution of any complaint asserting a cause
of action arising under the Securities Act." Please reconcile these disclosures.
            Please contact Jeanne Bennett at 202-551-3606 or Brian Cascio at 202-551-3676 if you
have questions regarding comments on the financial statements and related matters. Please
contact Jessica Ansart at 202-551-4511 or Lauren Nguyen at 202-551-3642 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Andy Tucker